Stocktoria

CURIS INC CRIS

Nasdaq · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2000-08-01 · LEI

CURIS INC financials (annual)

Revenue
$7.5M $9.9M $10.4M $10.0M $10.8M $10.6M $10.2M $10.0M $10.9M $9.4M 2016201720182019202020212022202320242025
Net income
-$60.4M -$53.3M -$32.6M -$32.1M -$29.9M -$45.4M -$56.7M -$47.4M -$43.4M -$7.6M 2016201720182019202020212022202320242025
Free cash flow
-$36.1M -$48.5M -$30.1M -$26.2M -$26.4M -$37.6M -$54.8M -$38.4M 2016201720182019202020212022202320242025

Bars are annual figures from 2016 to 2025; red bars are negative (a loss or cash outflow).

MetricFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue$9.4M$10.9M$10.0M$10.2M$10.6M$10.8M$10.0M$10.4M$9.9M$7.5M
R&D expense$18.0M
Operating income-$5.7M-$44.5M-$48.3M-$53.0M-$42.1M-$24.9M-$24.4M-$29.3M-$49.8M-$58.0M
Interest expense$0$0$791,000$3.9M$4.0M$2.8M
Income tax$0$0
Net income-$7.6M-$43.4M-$47.4M-$56.7M-$45.4M-$29.9M-$32.1M-$32.6M-$53.3M-$60.4M
EPS (diluted)$-0.58$-6.88$-8.96$-12.14$0.50$-0.61$-0.97
Operating cash flow-$27.2M-$39.6M-$38.4M-$54.3M-$37.6M-$25.7M-$26.2M-$30.1M-$48.4M-$35.8M
Free cash flow-$38.4M-$54.8M-$37.6M-$26.4M-$26.2M-$30.1M-$48.5M-$36.1M
Cash & equivalents$5.1M$20.0M$26.7M$19.7M$40.0M$129.6M$15.4M$23.6M$38.3M$26.0M
Total assets$20.0M$41.3M$77.3M$108.8M$162.3M$204.4M$35.1M$37.4M$73.8M$57.8M
Total liabilities$14.5M$47.3M$57.6M$62.3M$71.6M$73.7M$69.0M$41.9M$49.8M$28.5M
Shareholders' equity$5.5M-$6.0M$19.7M$46.6M$90.7M$130.7M-$33.9M-$4.5M$24.0M$29.5M

Growth · year-over-year · Revenue CAGR 2.6%

MetricFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue growth-13.4%+8.8%-1.4%-4.6%-1.7%+8.3%-4.1%+5.4%+31.5%-4.5%
EPS growth-2528.0%

Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.

Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.